Novavax, Inc. (NVV1.F)
EUR 5.7
(-3.99%)
EUR 5.7
(-3.99%)
| Year | Inventory | Inventory Growth |
|---|---|---|
| 2023 | 41.69 Million USD | 13.67% |
| 2022 | 36.68 Million USD | 101.87% |
| 2021 | -1.95 Billion USD | -1074.14% |
| 2020 | -166.67 Million USD | -100.89% |
| 2019 | -82.96 Million USD | -792.88% |
| 2018 | 11.97 Million USD | -8.49% |
| 2017 | 13.08 Million USD | -16.85% |
| 2016 | 15.73 Million USD | 0.0% |
| 2015 | - USD | 0.0% |
| 2014 | - USD | -100.0% |
| 2013 | 4.46 Million USD | 25.84% |
| 2012 | 3.54 Million USD | 45.23% |
| 2011 | 2.44 Million USD | 0.0% |
| 2010 | - USD | 0.0% |
| 2009 | - USD | -100.0% |
| 2008 | 42 Thousand USD | 68.0% |
| 2007 | 25 Thousand USD | -95.83% |
| 2006 | 600 Thousand USD | -25.0% |
| 2005 | 800 Thousand USD | -76.91% |
| 2004 | 3.46 Million USD | 305.15% |
| 2003 | 855 Thousand USD | 35.07% |
| 2002 | 633 Thousand USD | 17.88% |
| 2001 | 537 Thousand USD | 16.49% |
| 2000 | 461 Thousand USD | 0.0% |
| 1999 | - USD | 0.0% |
| 1998 | - USD | 0.0% |
| 1997 | - USD | 0.0% |
| 1996 | - USD | 0.0% |
| Year | Inventory | Inventory Growth |
|---|---|---|
| 2024 Q1 | 15.77 Million USD | -62.16% |
| 2024 Q2 | 9.17 Million USD | -41.87% |
| 2023 Q2 | 23.48 Million USD | -31.29% |
| 2023 Q4 | 41.69 Million USD | -40.09% |
| 2023 Q3 | 69.59 Million USD | 196.29% |
| 2023 Q1 | 34.18 Million USD | -6.81% |
| 2023 FY | 41.69 Million USD | 13.67% |
| 2022 FY | 36.68 Million USD | 101.87% |
| 2022 Q4 | 36.68 Million USD | -55.5% |
| 2022 Q3 | 82.43 Million USD | -67.84% |
| 2022 Q1 | 106.64 Million USD | 105.45% |
| 2022 Q2 | 256.3 Million USD | 140.32% |
| 2021 Q1 | 32.12 Million USD | 119.28% |
| 2021 Q2 | -2.09 Billion USD | -6631.32% |
| 2021 FY | -1.95 Billion USD | -1074.14% |
| 2021 Q4 | -1.95 Billion USD | -24038.42% |
| 2021 Q3 | 8.17 Million USD | 100.39% |
| 2020 Q3 | 67.15 Million USD | 0.0% |
| 2020 FY | -166.67 Million USD | -100.89% |
| 2020 Q2 | - USD | 0.0% |
| 2020 Q4 | -166.67 Million USD | -348.19% |
| 2020 Q1 | - USD | 100.0% |
| 2019 Q4 | -82.96 Million USD | 0.0% |
| 2019 FY | -82.96 Million USD | -792.88% |
| 2019 Q2 | - USD | 0.0% |
| 2019 Q1 | - USD | -100.0% |
| 2019 Q3 | - USD | 0.0% |
| 2018 Q3 | - USD | 0.0% |
| 2018 FY | 11.97 Million USD | -8.49% |
| 2018 Q1 | - USD | -100.0% |
| 2018 Q2 | - USD | 0.0% |
| 2018 Q4 | 11.97 Million USD | 0.0% |
| 2017 Q2 | - USD | 0.0% |
| 2017 Q1 | - USD | -100.0% |
| 2017 FY | 13.08 Million USD | -16.85% |
| 2017 Q4 | 13.08 Million USD | 0.0% |
| 2017 Q3 | - USD | 0.0% |
| 2016 Q4 | 15.73 Million USD | -50.08% |
| 2016 Q1 | 331.26 Million USD | 0.0% |
| 2016 Q2 | 33.31 Million USD | -89.94% |
| 2016 Q3 | 31.52 Million USD | -5.38% |
| 2016 FY | 15.73 Million USD | 0.0% |
| 2015 Q3 | - USD | -100.0% |
| 2015 FY | - USD | 0.0% |
| 2015 Q1 | - USD | 0.0% |
| 2015 Q4 | - USD | 0.0% |
| 2015 Q2 | 147.55 Million USD | 0.0% |
| 2014 Q1 | 4.96 Million USD | 11.23% |
| 2014 Q3 | 6.39 Million USD | 20.23% |
| 2014 Q4 | - USD | -100.0% |
| 2014 Q2 | 5.31 Million USD | 7.19% |
| 2014 FY | - USD | -100.0% |
| 2013 Q2 | 2.02 Million USD | -94.62% |
| 2013 Q4 | 4.46 Million USD | 42.07% |
| 2013 Q3 | 3.14 Million USD | 55.14% |
| 2013 Q1 | 37.64 Million USD | 961.78% |
| 2013 FY | 4.46 Million USD | 25.84% |
| 2012 Q3 | 3.64 Million USD | 48.65% |
| 2012 FY | 3.54 Million USD | 45.23% |
| 2012 Q1 | 2.41 Million USD | -1.23% |
| 2012 Q2 | 2.45 Million USD | 1.7% |
| 2012 Q4 | 3.54 Million USD | -2.74% |
| 2011 Q3 | 2.39 Million USD | 0.0% |
| 2011 Q2 | - USD | 0.0% |
| 2011 Q1 | - USD | 0.0% |
| 2011 FY | 2.44 Million USD | 0.0% |
| 2011 Q4 | 2.44 Million USD | 2.05% |
| 2010 Q1 | - USD | 0.0% |
| 2010 FY | - USD | 0.0% |
| 2010 Q3 | - USD | 0.0% |
| 2010 Q4 | - USD | 0.0% |
| 2010 Q2 | - USD | 0.0% |
| 2009 FY | - USD | -100.0% |
| 2009 Q2 | - USD | 0.0% |
| 2009 Q3 | - USD | 0.0% |
| 2009 Q4 | - USD | 0.0% |
| 2009 Q1 | - USD | -100.0% |
| 2008 Q3 | 55 Thousand USD | 17.02% |
| 2008 Q2 | 47 Thousand USD | 9.3% |
| 2008 Q1 | 43 Thousand USD | 72.0% |
| 2008 FY | 42 Thousand USD | 68.0% |
| 2008 Q4 | 42 Thousand USD | -23.64% |
| 2007 Q3 | 498 Thousand USD | 12.16% |
| 2007 FY | 25 Thousand USD | -95.83% |
| 2007 Q1 | 735 Thousand USD | 22.5% |
| 2007 Q2 | 444 Thousand USD | -39.59% |
| 2007 Q4 | 25 Thousand USD | -94.98% |
| 2006 Q2 | 757 Thousand USD | -2.95% |
| 2006 Q1 | 780 Thousand USD | -2.5% |
| 2006 FY | 600 Thousand USD | -25.0% |
| 2006 Q4 | 600 Thousand USD | -33.33% |
| 2006 Q3 | 900 Thousand USD | 18.89% |
| 2005 Q4 | 800 Thousand USD | -51.54% |
| 2005 FY | 800 Thousand USD | -76.91% |
| 2005 Q3 | 1.65 Million USD | 17.93% |
| 2005 Q1 | 2.37 Million USD | -31.52% |
| 2005 Q2 | 1.4 Million USD | -40.98% |
| 2004 Q4 | 3.46 Million USD | 52.06% |
| 2004 Q3 | 2.27 Million USD | 204.95% |
| 2004 Q2 | 747 Thousand USD | -14.33% |
| 2004 Q1 | 872 Thousand USD | 1.99% |
| 2004 FY | 3.46 Million USD | 305.15% |
| 2003 FY | 855 Thousand USD | 35.07% |
| 2003 Q4 | 855 Thousand USD | 16.96% |
| 2003 Q3 | 731 Thousand USD | -8.74% |
| 2003 Q1 | 630 Thousand USD | -0.47% |
| 2003 Q2 | 801 Thousand USD | 27.14% |
| 2002 Q2 | 655 Thousand USD | -27.7% |
| 2002 Q3 | 930 Thousand USD | 41.98% |
| 2002 Q4 | 633 Thousand USD | -31.94% |
| 2002 FY | 633 Thousand USD | 17.88% |
| 2002 Q1 | 906 Thousand USD | 68.72% |
| 2001 Q2 | 825 Thousand USD | 34.8% |
| 2001 FY | 537 Thousand USD | 16.49% |
| 2001 Q1 | 612 Thousand USD | 32.75% |
| 2001 Q4 | 537 Thousand USD | -18.51% |
| 2001 Q3 | 659 Thousand USD | -20.12% |
| 2000 Q2 | - USD | 0.0% |
| 2000 Q1 | - USD | 0.0% |
| 2000 Q3 | - USD | 0.0% |
| 2000 Q4 | 461 Thousand USD | 0.0% |
| 2000 FY | 461 Thousand USD | 0.0% |
| 1999 Q4 | - USD | 0.0% |
| 1999 Q2 | - USD | 0.0% |
| 1999 Q1 | - USD | 0.0% |
| 1999 Q3 | - USD | 0.0% |
| 1999 FY | - USD | 0.0% |
| 1998 Q1 | - USD | 0.0% |
| 1998 Q4 | - USD | 0.0% |
| 1998 Q2 | - USD | 0.0% |
| 1998 FY | - USD | 0.0% |
| 1998 Q3 | - USD | 0.0% |
| 1997 Q4 | - USD | 0.0% |
| 1997 FY | - USD | 0.0% |
| 1997 Q2 | - USD | 0.0% |
| 1997 Q1 | - USD | 0.0% |
| 1997 Q3 | - USD | 0.0% |
| 1996 Q2 | - USD | 0.0% |
| 1996 Q4 | - USD | 0.0% |
| 1996 Q3 | - USD | 0.0% |
| 1996 Q1 | - USD | 0.0% |
| 1996 FY | - USD | 0.0% |
| Name | Inventory | Inventory Difference |
|---|---|---|
| BioNTech SE | 357.7 Million EUR | 88.343% |
| CureVac N.V. | 24.82 Million EUR | -67.984% |
| Biotest Aktiengesellschaft | 419.1 Million EUR | 90.051% |
| Biotest Aktiengesellschaft | 419.1 Million EUR | 90.051% |
| BRAIN Biotech AG | 9.72 Million EUR | -328.707% |
| Formycon AG | 467 Thousand EUR | -8828.48% |
| Heidelberg Pharma AG | 10.48 Million EUR | -297.567% |
| Medigene AG | 1.00 EUR | -4169599900.0% |